Clinical significance of cytochrome P450 genetic polymorphism – Part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2

1. Gonzalez, F. J., Gelboin, H. V.: Human Cytochrome P450: Evolution and cDNA-directed expression. Environ. Health Perspect. 1992; 98, 81–85.

2. Omiecinski, C. J., Remmel, R. P., Hosagrahara, V.P.: Concise review of the cytochrome P450s and their roles in toxicology. Toxicol. Sci. 1999; 48, 151–156.

3. Chang, G. W., Kam, P. C.: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999; 54, 42–50.

4. Anzenbacher, P, Anzenbacherová, E.: Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life. Sci. 2001; 58, 737–747.

5. Guengerich, F. P.: Cytochrome P450: What have we learned and what are the future issues? Drug. Metab. Rev. 2004; 36, 159–197.

6. Soucek, P., Gut, I.: Co je to cytochrom P 450? Enzymatické formy cytochromu P450 – dosažený stupeň znalostí. Cas. Lek. Cesk. 1993; 12, 353–358.

7. Guengerich, F. P.: Cytochromes P450, drugs and diseases. Mol. Interv. 2003; 3, 194–204.

8. Guengerich, F. P.: Cytochrome P450s and other enzymes in drug metabolism and toxicity. The APPS J. 2006; 8, E101–110.

9. Guengerich, F. P.: Update information on human P450s. Drug. Metab. Rev. 2002; 34, 7–15.

10. Güzey, C., Spigset, O.: Genotyping as a tool to predict adverse drug reactions. Curr. TP. Med. Chem. 2004; 4, 1411–1421.

11. Rogers, J. F., Nafzinger, A. N., Bertino, J. S.: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450 – metabolized drugs. Am. J. Med. 2002; 113, 746–750.

12. Buzková, H., Pechandová, K., Slanař, O., Perlík, F.: Genetic polymorphism of cytochrome P450 and methods for its determination. Prague. Med. Rep. 2006; 107: 383–393.

13. Dahl, M. L.: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Useful aid to Prescribing? Clin. Pharmacokinet. 2002; 41, 453–470.

14. Home page of the human cytochrome P450 (CYP 2D6) allele nomenclature (updated 2010 July 20). Available from: http://www.cypalleles.ki.se/cyp2d6.htm

15. Bertilsson, L.: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 1995; 29, 192–209.

16. Ingelman-Sundberg, M.: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends. Pharmacol. Sci. 2004; 25, 193–200.

17. Pirmohamed, M., Park, B. K.: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192, 23–32.

18. Steiner, E., Iselius, L., Alván, G., Lindsten, J., Sjöqvist, F.: A family study of genetic and environmental factors determing polymorphic hydroxylation of debrisoquin. Clin. Pharmacol. Ther. 1985; 38, 394–401.

19. Aklillu, E., Herrlin, K., Gustafsson, L. L., Bertilsson, L., Ingelman-Sundberg, M.: Evidence for environmental influence on CYP2D6-cataysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living or in Sweden. Pharmacogenetics 2002; 12, 375–383.

20. Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., Zanger, U. M.: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38, 978–988.

21. Villeneuve, J. P., Pichette, V.: Cytochrome P450 and liver diseases. Curr. Drug. Metab. 2004; 5, 273–282.

22. Tracy, T. S., Venkataramanan, R., Glover, D., Caritis, S. N.: Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A4 activity) during pregnancy. Am J Obstet. Gynecol. 2005; 192, 633–639.

23. Schaffer, S. D., Yoon, S., Zadezensky, I.: A review of smoking cessation: potentially risky effects on prescribed medications. J. Clin. Nurs. 2009; 18, 1533–1540.

24. Nekvidová, J., Anzenbacher, P.: Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes. Ces slov. Farm. 2007; 56, 165–173.

25. Guengerich, F. P.: Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am. J. Clin. Nutr. 1995; 61, 651–658.

26. Tanaka E., Hisawa S.: Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J. Clin. Pharm. Ther. 1999; 24, 7–16.

27. Perucca, E.: Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2005; 61, 246–255.

28. Jain, K. K.: Applications of AmpliChip CYP450. Mol. Diagn. 2005; 9, 119–127.

29. Pucci, L., Geppetti, A., Maggini, V., Lucchesi, D., Maria Rossi A., Longo V.: CYP1A2 F21L and F186L polymorphisms in an Italian population sample. Drug Metab. Pharmacokinet. 2007; 22, 220–222.

30. Ghotbi, R., Christensen, M., Roh, H., Ingelman-Sundberg M., Aklillu E, Bertilsson L.: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 2007; 63, 537–546.

31. Sachse, C., Brockmöller, J., Bauer, S., Roots, I.: Functional signifance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 1999; 47, 445–449.

32. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M., Kamataki, T.: Genetic polymorphism in the 5’-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 1999;125, 803–808.

33. Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman K., Pitarque M., Bertilsson L., Ingelman-Sundberg M.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 2003; 64, 659–69.

34. Relling, M. V., Lin, J. S., Ayers, G. D., Evans, W. E.: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A activities. Clin. Pharmacol. Ther. 1992; 52, 643–658.

35. Zhou, S. F., Yang, L. P., Zhou, Z. W., Liu, Y. H., Chan, E.: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009; 11: 481–494.

36. Uslu, A., Ogus, C., Ozdemir, T., Bilgen, T., Tosun, O., Keser, I.: The effect of CYP1A2 gene polymorphism on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep. 2010; 43, 530–534.

37. Obase, Y, Shimoda, T, Kawano, T, Saeki, S., Tomari, S. Y., Mitsuta-Izaki, K., Matsuse, H., Kinoshita, M., Kohno, S.: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with astma. Clin. Pharmacol. Ther. 2003; 73, 468–474.

38. Eap, C. B., Bender, .S, Jaquenoud Sirot, E., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., Broly, F.: Nonresponse to clozapine and ultrarapid CYP1A2 activity: Clinical data and analysis of CYP1A2 gene. J. Clin. Psychopharmacol. 2004; 24, 214–219.

39. Ozdemir, V., Kalow, W., Okey, A. B., Lam, M. S., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., Roy, R.: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J. Clin. Psychopharmacol. 2001; 21, 603–606.

40. Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C. B.: Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther. Drug. Monit. 2005; 27, 539–543.

41. Jaquenoud Sirot, E., Knezevic, B., Morena, G. P., Harenberg, S., Oneda, B., Crettol, S., Ansermot, N., Baumann, P., Eap, C. B.: ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J. Clin. Psychopharmacol. 2009; 29, 319–326.

42. Kootstra-Ros, J. E., Smallegoor, W., van der Weide, J.: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann. Clin. Biochem. 2005; 42, 216–219.

43. Laika, B., Leucht, S., Heres, S., Schneider, H., Steimer, W.: Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010; 10, 20–29.

44. Shirley, K. L., Hon, Y. Y., Penzak, S. R., Lam, Y. W., Spratlin, V., Jann, M. W.: Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003; 28, 961–966.

45. Bohanec Grabar, P., Rozman, B., Tomsic, M., Suput, D., Logar, D., Dolzan, V.: Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 2008; 64, 871–876.

46. Fuhr, U., Rost, K. L.: Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4, 109–116.

47. Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., Santonastaso, M.: CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J. Hypertens. 2009; 27, 1594–1601.

48. Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., Campos, H.: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295, 1135–1141.